Active Biotech and Ipsen have dropped development of the immunotherapy candidate tasquinimod in prostate cancer after its "unambiguous" failure in a Phase III trial.
The market capitalization of Active Biotech, the drug's originator, fell over 61% on the news while that of licensee Ipsen...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?